News
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71...
News
HDAC/HMA combo shows ‘remarkable’ activity in PTCL
LUGANO, SWITZERLAND – Patients with AITL and PTCL-TFH subtypes had high overall response rates to romidepsin and AZA.
News
Bevacizumab or pemetrexed, but not both, efficacious for NSCLC maintenance
The combination of bevacizumab and pemetrexed did not improve survival and had significantly worse toxicity than bevacizumab alone.
News
High EPclin score equals chemo benefit in ER+/HER2– breast cancer
Women with high EPclin scores would be likely to have an absolute benefit from chemotherapy added to endocrine therapy, a mathematical model...
News
ctDNA may predict relapse risk in early breast cancer
Circulating tumor DNA was associated with a significant risk for relapse in women treated for early primary breast cancers.
News
Mixed results with TMB as NSCLC marker
Tumor mutational burden in non–small cell lung cancer varies according to histology and tumor sample location.
News
BRCA2 mutations linked to childhood NHL
Survivors of childhood non-Hodgkin may be at significantly increased risk for breast, ovarian, prostate, and other BRCA2-associated cancers.
News
Study outlines survival factors with nivolumab
Absence of bone or liver metastases and excellent baseline performance status are linked to 5-year OS in melanoma, RCC, and NSCLC treated with...
News
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
LUGANO, SWITZERLAND – Lenalidomide plus the anti-CD19 antibody tafasitamab was associated with a 60% overall response rate.
News
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
News
Acalabrutinib extends PFS in advanced CLL
AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...
News
Ibrutinib tops chlorambucil against CLL
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
News
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
News
No benefit with rituximab after first CR in DLBCL
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP...
News
AML variants before transplant signal need for aggressive therapy
AMSTERDAM – Patients who had genomic evidence of a lingering AML variant had worse posttransplant outcomes when they underwent reduced-intensity...